All In Biotech

Investigational drug · Phase 2

HB-201

Also called: HB-202 alternating using CD8 PET Tracer, Zr-Df-IAB22M2C

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for HPV-Related Squamous Cell Carcinoma.

Phase 2

Last checked: Nov 19, 2026Latest source record: Sep 15, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

0 still active

All registered trials

5

Any phase or sponsor naming "HB-201"

First trial start

2019

Dec 11, 2019

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "HB-201", any sponsor or status.

Conditions studied

As listed on its trial records.

  • HPV-Related Squamous Cell Carcinoma

Approved drugs for the same conditions: Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "HB-201" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 72 on PubMed

Also in development for HPV-Related Squamous Cell Carcinoma

  • HB-202Phase 21 trial

    Hookipa Biotech GmbH · HPV-Related Squamous Cell Carcinoma

  • SCG142Phase 21 trial

    SCG Cell Therapy Pte. Ltd. · HPV-Related Squamous Cell Carcinoma, HPV-Related Cervical Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.